Abstract:Abstract Background Angiopoietin-like protein 3 (ANGPTL3) is secreted by hepatocytes and inhibits lipoprotein lipase and endothelial lipase activity. Previous studies reported the correlation between plasma ANGPTL3 levels and high-density lipoprotein (HDL). Recently ANGPTL3 was found to preferentially bind to HDL in healthy human circulation. Here, we examined whether ANGPTL3, as a component of HDL, modulates HDL function and affects HDL other components in human and mice with non-diabetes or type 2 diabetes mellitus. Methods HDL was isolated from the plasma of female non-diabetic subjects and type-2 diabetic mellitus (T2DM) patients. Immunoprecipitation, western blot, and ELISA assays were used to examine ANGPTL3 levels in HDL. Db/m and db/db mice, AAV virus mediated ANGPTL3 overexpression and knockdown models and ANGPTL3 knockout mice were used. The cholesterol efflux capacity induced by HDL was analyzed in macrophages preloaded with fluorescent cholesterol. The anti-inflammation capacity of HDL was assessed using flow cytometry to measure VCAM-1 and ICAM-1 expression levels in TNF-α-stimulated endothelial cells pretreated with HDL. Results ANGPTL3 was found to bind to HDL and be a component of HDL in both non-diabetic subjects and T2DM patients. Flag-ANGPTL3 was found in the HDL of transgenic mice overexpressing Flag-ANGPTL3. ANGPLT3 of HDL was positively associated with cholesterol efflux in female non-diabetic controls (r = 0.4102, p = 0.0117) but not in female T2DM patients (r = − 0.1725, p = 0.3224). Lower ANGPTL3 levels of HDL were found in diabetic (db/db) mice compared to control (db/m) mice and were associated with reduced cholesterol efflux and inhibition of VCAM-1 and ICAM-1 expression in endothelial cells (p < 0.05 for all). Following AAV-mediated ANGPTL3 cDNA transfer in db/db mice, ANGPTL3 levels were found to be increased in HDL, and corresponded to increased cholesterol efflux and decreased ICAM-1 expression. In contrast, knockdown of ANGPTL3 levels in HDL by AAV-mediated shRNA transfer led to a reduction in HDL function (p < 0.05 for both). Plasma total cholesterol, total triglycerides, HDL-c, protein components of HDL and the cholesterol efflux function of HDL were lower in ANGPTL3−/− mice than ANGPTL3+/+ mice, suggesting that ANGPTL3 in HDL may regulate HDL function by disrupting the balance of protein components in HDL. Conclusion ANGPTL3 was identified as a component of HDL in humans and mice. ANGPTL3 of HDL regulated cholesterol efflux and the anti-inflammatory functions of HDL in T2DM mice. Both the protein components of HDL and cholesterol efflux capacity of HDL were decreased in ANGPTL3−/− mice. Our findings suggest that ANGPTL3 in HDL may regulate HDL function by disrupting the balance of protein components in HDL. Our study contributes to a more comprehensive understanding of the role of ANGPTL3 in lipid metabolism.

The negative effect of ANGPTL8 on HDL-mediated cholesterol efflux capacity

Apolipoprotein CIII May Mediate the Impacts of Angiopoietin-Like Protein 8 on Triglyceride Metabolism

Angiopoietin-like protein 8 accelerates atherosclerosis in ApoE−/− mice

ANGPTL3 is a novel HDL component that regulates HDL function

Associations of Circulating ANGPTL3, C-Terminal Domain-Containing ANGPTL4, and ANGPTL3/8 and ANGPTL4/8 Complexes with LPL Activity, Diabetes, Inflammation, and Cardiovascular Mortality

Circulating ANGPTL8 levels and risk of kidney function decline: Results from the 4C Study

ANGPTL3 Is Involved in the Post-prandial Response in Triglyceride-Rich Lipoproteins and HDL Components in Patients With Coronary Artery Disease

Angiopoietin‐like Protein 8/betatrophin Correlates with Hepatocellular Lipid Content Independent of Insulin Resistance in Non‐alcoholic Fatty Liver Disease Patients

Association of Circulating ANGPTL8 Levels With Renal Dysfunction: A Case-Control Study

Predictive Values of ANGPTL8 on Risk of All-Cause Mortality in Diabetic Patients: Results from the REACTION Study

The Effects of Serum ANGPTL8/betatrophin on the Risk of Developing the Metabolic Syndrome – A Prospective Study

Circulating ANGPTL3 and ANGPTL4 Levels Predict Coronary Artery Atherosclerosis Severity

New Insights into ANGPLT3 in Controlling Lipoprotein Metabolism and Risk of Cardiovascular Diseases

Increased ANGPTL3, 4 and ANGPTL8/betatrophin expression levels in obesity and T2D

Angiopoietin-like protein 8: An attractive biomarker for the evaluation of subjects with insulin resistance and related disorders

ANGPTL8 is a negative regulator in pathological cardiac hypertrophy

Angiopoietin-Like Protein 4 May Be an Interplay Between Serum Uric Acid and Triglyceride-Rich Lipoprotein Cholesterol

Angiopoietin-Like 3 (ANGPTL3) and Atherosclerosis: Lipid and Non-Lipid Related Effects

ANGPTL8: an Important Regulator in Metabolic Disorders

Genetic inhibition of angiopoietin-like protein-3, lipids, and cardiometabolic risk

Angiopoietin-like Proteins 3, 4 and 8: Regulating Lipid Metabolism and Providing New Hope for Metabolic Syndrome